Search results
Results from the WOW.Com Content Network
Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. [11] Some clinical trial results were announced in 2017. [12] On 26 November 2018, Larotrectinib was approved by the FDA. [13]
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
[3] [4] It is a decapeptide (pGlu-His-Trp-Ser-Tyr- D -Trp-Leu-Arg-Pro-Gly-NH 2 ) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts . Primary indications include endometriosis , [ 5 ] for the reduction of uterine fibroids , to treat prostate cancer , and to treat male hypersexuality with severe ...
[11] [10] [12] To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. [ 4 ] [ 2 ] [ 13 ] Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings.
Levetiracetam has not been found to be useful for treatment of neuropathic pain, [26] nor for treatment of essential tremors. [27] Levetiracetam has not been found to be useful for treating all developmental disorders within the autism spectrum; [28] [29] studies have only proven to be an effective treatment for partial, myoclonic, or tonic-clonic seizures associated with autism spectrum disorder.
The US retail price of etanercept has risen over time. In 2008, the cost of etanercept was $1,500 per month or $18,000 per year. [ 50 ] By 2011, the cost had exceeded $20,000 per year.
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...